Summary
According to the recently published report 'Toll Like Receptor 8 - Drugs In Development, 2022'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 35 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It controls host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 8 - Drugs In Development, 2022' outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 7, 12 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecule, respectively.
Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Hepatitis B, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Gastric Cancer, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cervical Cancer, Cutaneous Lupus Erythematosus, Fibrosis, Gastroesophageal (GE) Junction Carcinomas, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Nasopharyngeal Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anal Cancer, Arthritis, Chondrosarcoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Endometrial Cancer, Esophageal Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hypopharyngeal Cancer, Inflammation, Kaposi Sarcoma, Laryngeal Cancer, Leiomyosarcoma, Leukemia, Medullary Thyroid Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Osteosarcoma, Pancreatic Cancer, Penile Cancer, Pleomorphic Liposarcoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Subacute Cutaneous Lupus Erythematosus (SCLE), Synovial Sarcoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 8 (CD288 or TLR8)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
Altimmune Inc
Ambrx Biopharma Inc
Ascendis Pharma AS
Avidea Technologies Inc
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac NV
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Merck KGaA
Nektar Therapeutics
Novartis AG
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Seven and Eight Biopharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Zhimeng Biopharma Inc
Silverback Therapeutics Inc
UroGen Pharma Ltd
Vaccex Inc
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
afimetoran - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALT-702 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BDB-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BDB-018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BDB-030 - Drug Profile
Product Description
Mechanism Of Action
BDB-102 - Drug Profile
Product Description
Mechanism Of Action
BDC-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CB06-036 - Drug Profile
Product Description
Mechanism Of Action
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
CV-8102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DN-1508052 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Agonize TLR8 for Fibrosis and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
E-6742 - Drug Profile
Product Description
Mechanism Of Action
History of Events
enpatoran - Drug Profile
Product Description
Mechanism Of Action
History of Events
HRS-9950 - Drug Profile
Product Description
Mechanism Of Action
imiquimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
imiquimod + zalifrelimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
INGMM-1 - Drug Profile
Product Description
Mechanism Of Action
JB-6121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody Conjugates to Agonize TLR 7 and 8 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
motolimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
NKTR-262 - Drug Profile
Product Description
Mechanism Of Action
History of Events
resiquimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
resiquimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
resiquimod SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
RSLV-132 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBT-6050 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBT-6290 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBT-8230 - Drug Profile
Product Description
Mechanism Of Action
History of Events
selgantolimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize TLR7 and TLR8 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize TLR7 and TLR8 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize TLR8 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYN-001 - Drug Profile
Product Description
Mechanism Of Action
VTX-1463 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Jan 06, 2022: Bolt Biotherapeutics doses first patient with BDC-1001 in combination with OPDIVO (nivolumab) in ongoing phase 1/2 clinical trial for the Treatment of HER2-expressing solid tumors
Dec 14, 2021: Ascendis Pharma virtual R&D program update highlights continued development across R&D pipeline
Dec 07, 2021: Ascendis Pharma to host virtual R&D program update on December 14
Dec 06, 2021: Bolt Biotherapeutics reports interim BDC-1001 phase 1/2 data demonstrating a safe and well-tolerated profile and emerging clinical activity at the ESMO Immuno-Oncology Congress 2021
Dec 02, 2021: Bolt Biotherapeutics to present interim clinical data on BDC-1001 phase 1/2 clinical trial at ESMO Immuno-Oncology Congress 2021
Nov 13, 2021: Seven and Eight Biopharma’s BDB001 in combination with an anti-PD-L1 mAb shows favorable safety and clinical responses in interim phase 1 data presented at the 2021 SITC Annual Meeting
Nov 12, 2021: Silverback Therapeutics presents preclinical data for SBT8230 at AASLD The Liver Meeting 2021
Nov 12, 2021: Silverback Therapeutics presents SBT6050-201 trial in progress poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Nov 10, 2021: CureVac presents promising data at SITC from Phase 1 study of oncology candidate CV8102 showing systemic immune response
Nov 09, 2021: Ascendis Pharma presents new non-clinical data for TransCon TLR7/8 agonist oncology program at SITC 2021
Sep 16, 2021: Silverback Therapeutics presents interim clinical results from the ongoing phase 1/1b study of SBT6050 alone or in combination with Pembrolizumab in patients with advanced or metastatic HER2-expressing solid tumors
Sep 13, 2021: Silverback Therapeutics to present data from its phase 1/1b clinical trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
Sep 07, 2021: Seven and Eight Biopharmaceuticals announces the first patient treated in a phase 2 clinical trial of the TLR 7/8 dual agonist BDB001 in anti-PD-1 / anti-PD-L1 refractory solid tumors
Jun 24, 2021: Resolve Therapeutics to start Phase II Trial of RSLV-132 for long Covid
Jun 23, 2021: Seven and Eight Biopharmaceuticals announces the first patient treated in a first-in-human clinical trial of the TLR7/8 dual agonist BDB018 in advanced solid tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Altimmune Inc, 2022
Pipeline by Ambrx Biopharma Inc, 2022
Pipeline by Ascendis Pharma AS, 2022
Pipeline by Avidea Technologies Inc, 2022
Pipeline by Bolt Biotherapeutics Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Curebiotech Inc, 2022
Pipeline by Curevac NV, 2022
Pipeline by Dynavax Technologies Corp, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Galderma SA, 2022
Pipeline by Gilead Sciences Inc, 2022
Pipeline by IngenoVax LLC, 2022
Pipeline by Janus Biotherapeutics Inc, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pipeline by Merck KGaA, 2022
Pipeline by Nektar Therapeutics, 2022
Pipeline by Novartis AG, 2022
Pipeline by Resolve Therapeutics LLC, 2022
Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022
Pipeline by Seven and Eight Biopharmaceuticals Inc, 2022
Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Pipeline by Shanghai Zhimeng Biopharma Inc, 2022
Pipeline by Silverback Therapeutics Inc, 2022
Pipeline by UroGen Pharma Ltd, 2022
Pipeline by Vaccex Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
